Attached files
| file | filename |
|---|---|
| EX-99.2 - INTERLEUKIN GENETICS INC | v194296_ex99-2.htm |
| EX-99.1 - INTERLEUKIN GENETICS INC | v194296_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM 8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 OR 15(D) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): August 11,
2010
Interleukin
Genetics, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State or
Other Jurisdiction of Incorporation)
|
001-32715
|
94-3123681
|
|
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
|
|
135
Beaver Street Waltham, MA
|
02452
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(781)
398-0700
(Registrant’s
Telephone Number, Including Area Code)
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
o
|
Written communications pursuant
to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
3.01 Notice
of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;
Transfer of Listing.
As
previously reported, on June 24, 2010, Interleukin Genetics, Inc. (the
“Company”) received a notice from NYSE Amex LLC (the “Exchange”) that it
intended to initiate delisting proceedings because the Company had failed to
regain compliance with Section 1003(a)(iii) of the Exchange’s Company Guide due
to stockholders’ equity of less than $6,000,000 and losses from continuing
operations and/or net losses in its five most recent fiscal years. The Company
requested a hearing before a Listing Qualifications Panel (the “Panel”) to
appeal the Exchange’s delisting determination. Despite the Company’s continued
attempts to regain compliance, the Company determined that it was not possible
to regain compliance with Section 1003(a)(iii) by the time of the scheduled
hearing date and that any further appeal of the Exchange’s determination would
not be successful. Accordingly, on August 11, 2010, the Company’s Board of
Directors authorized the Company to withdraw the appeal of the Exchange’s
delisting determination and to pursue transfer of the trading of the Company’s
common stock to the OTCQB™
Marketplace. As a result, the Company’s common stock was suspended from the
Exchange and began trading on the OTCQB™ under
the symbol “ILIU” effective with the open of business on Monday, August 16,
2010.
On August
16, 2010, the Company issued a press release to report the transfer of trading
of its common stock from the Exchange to the OTCQB™. A
copy of that press release is attached to this Current Report on Form 8-K
as Exhibit 99.1 and is incorporated herein by reference.
ITEM
8.01 Other
Events
On August
12, 2010, Interleukin Genetics, Inc. (the “Company”) issued a press release
announcing it had signed an agreement with the University of Michigan to conduct
a study on risk factors predictive of periodontal disease progression to tooth
loss using a new version of the Company’s PST genetic test. A copy of
the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K
and is incorporated herein by reference.
ITEM
9.01 Financial
Statements and Exhibits.
(d) Exhibits.
|
Exhibit
Number
|
Description of Exhibit
|
|
|
99.1
|
Press
release dated August 16, 2010.
|
|
|
99.2
|
Press
release dated August 12,
2010.
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Interleukin
Genetics, Inc.
|
||
|
(Registrant)
|
||
|
Date: August
16, 2010
|
/s/
ELIOT M. LURIER
|
|
|
Eliot
M. Lurier
|
||
|
Chief
Financial Officer
|
||
|
(Signature)
|